HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A novel N-hydroxy-N'-aminoguanidine derivative inhibits ribonucleotide reductase activity: Effects in human HL-60 promyelocytic leukemia cells and synergism with arabinofuranosylcytosine (Ara-C).

Abstract
Ribonucleotide reductase (RR; EC 1.17.4.1) is responsible for the de novo conversion of ribonucleoside diphosphates into deoxyribonucleoside diphosphates, which are essential for DNA replication. RR is upregulated in tumor cells and therefore considered to be an excellent target for cancer chemotherapy. ABNM-13 (N-hydroxy-2-(anthracene-2-yl-methylene)-hydrazinecarboximidamide), a novel N-hydroxy-N'-aminoguanidine has been designed to inhibit RR activity using 3D molecular space modeling techniques. In this study, we evaluated its effect on human HL-60 promyelocytic leukemia cells. ABNM-13 proved to be a potent inhibitor of RR which was displayed by significant alterations of deoxyribonucleoside triphosphate (dNTP) pool balance and a highly significant decrease of incorporation of radiolabeled cytidine into DNA of HL-60 cells. Diminished RR activity caused replication stress which was consistent with activation of Chk1 and Chk2, resulting in downregulation/degradation of Cdc25A. In contrast, Cdc25B was upregulated, leading to dephosphorylation and activation of Cdk1. The combined disregulation of Cdc25A and Cdc25B was the most likely cause for ABNM-13 induced S-phase arrest. Finally, we combined ABNM-13 with the first-line antileukemic agent arabinofuranosylcytosine (Ara-C) and found that ABNM-13 synergistically potentiated the antineoplastic effects of Ara-C. Due to these promising results, ABNM-13 deserves further preclinical and in vivo testing.
AuthorsPhilipp Saiko, Geraldine Graser, Benedikt Giessrigl, Andreas Lackner, Michael Grusch, Georg Krupitza, Arijit Basu, Barij Nayan Sinha, Venkatesan Jayaprakash, Walter Jaeger, Monika Fritzer-Szekeres, Thomas Szekeres
JournalBiochemical pharmacology (Biochem Pharmacol) Vol. 81 Issue 1 Pg. 50-9 (Jan 01 2011) ISSN: 1873-2968 [Electronic] England
PMID20849828 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2010 Elsevier Inc. All rights reserved.
Chemical References
  • Cell Cycle Proteins
  • Guanidines
  • Immunoglobulin G
  • antineoplastic agent K 18
  • Cytarabine
  • N-hydroxy-N'-aminoguanidine
  • Ribonucleotide Reductases
  • Melphalan
Topics
  • Cell Cycle Proteins (genetics, metabolism)
  • Cytarabine (pharmacology)
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Gene Expression Regulation, Neoplastic
  • Guanidines (chemistry, pharmacology)
  • HL-60 Cells
  • Humans
  • Immunoglobulin G (chemistry, pharmacology)
  • Melphalan (chemistry, pharmacology)
  • Molecular Structure
  • Ribonucleotide Reductases (antagonists & inhibitors)
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: